Skip to main content
Chongqing Pharscin Pharmaceutical Co., Ltd. logo

Chongqing Pharscin Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 002907 ISIN · CNE100003308 LEI · 300300M2F5XMGFAYMA24 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,121 across all filing types
Latest filing 2025-05-21 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 002907

About Chongqing Pharscin Pharmaceutical Co., Ltd.

https://www.pharscin.com

Chongqing Pharscin Pharmaceutical Co., Ltd. is an integrated enterprise specializing in the research, development, production, and commercialization of chemical drugs and modern traditional Chinese medicine. The company focuses on therapeutic areas such as digestive system health, cardiovascular and cerebrovascular diseases, and hepatobiliary conditions. Its portfolio includes a variety of proprietary formulations and generic medications, notably treatments for chronic liver disease and gastrointestinal disorders. Pharscin maintains advanced manufacturing facilities and a dedicated R&D infrastructure focused on enhancing drug efficacy and delivery systems. The organization emphasizes clinical value and technological innovation to provide comprehensive healthcare solutions across diverse medical sectors.

Recent filings

Filing Released Lang Actions
关于董事会完成换届并聘任高级管理人员及其他人员的公告
Board/Management Information Classification · 95% confidence The document is an announcement from Chongqing Huashen Pharmaceutical Co., Ltd. regarding the completion of the board of directors' re-election and the appointment of senior management and other personnel. It details the composition of the new board, committee memberships, and biographies of the newly appointed directors and executives. There is no financial data, earnings information, or regulatory filings related to financial performance. The content focuses on management and board changes, which aligns with the category for announcements about changes in the company's board of directors or senior management. Therefore, the document fits the 'Board/Management Information' category (MANG). The document length (8474 characters) and detailed personnel information support this classification with high confidence.
2025-05-21 Chinese
董事会审计委员会工作细则（2025年4月）
Governance Information Classification · 95% confidence The document is a detailed set of rules and procedures for the Audit Committee of the Board of Directors of Chongqing Huashen Pharmaceutical Co., Ltd. It outlines the committee's composition, responsibilities, meeting procedures, and oversight mechanisms. It does not contain financial statements, audit opinions, or results of audits, but rather governance and procedural guidelines related to audit oversight. This fits the category of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices. The document length is 4598 characters, which is sufficient for a detailed governance document, and it is not an announcement or a brief notice. Therefore, the appropriate classification is CGR with high confidence.
2025-05-21 Chinese
上海泽昌律师事务所关于重庆华森制药股份有限公司2024年年度股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the 2024 Annual General Meeting (AGM) of Chongqing Huashen Pharmaceutical Co., Ltd. It details the legality of the AGM's convening, attendance, agenda, and voting results. The document includes detailed voting results on various resolutions including approval of the 2024 annual report, board reports, financial statements, profit distribution plan, remuneration, and election of directors. The document is not the annual report itself but a legal opinion on the AGM proceedings and voting outcomes. This fits the definition of Declaration of Voting Results & Voting Rights Announcements (DVA), as it officially reports the results of shareholder votes at the AGM. The document length (7971 characters) and content confirm it is a detailed voting results announcement rather than a brief notice or a full report like an annual report or management report.
2025-05-21 Chinese
独立董事工作细则（2025年4月）
Governance Information Classification · 95% confidence The document is a detailed set of rules and guidelines regarding the role, responsibilities, nomination, election, and legal duties of independent directors at a company. It references company law, securities law, stock exchange listing rules, and governance practices. It does not contain financial statements, earnings data, or audit results. It is not an announcement or a brief summary but a comprehensive governance document focused on board structure and director duties. Therefore, it fits best under Governance Information (CGR). The document length and detail confirm it is not a mere announcement or a short notice.
2025-05-21 Chinese
第三届董事会第十七次会议决议公告
Board/Management Information Classification · 100% confidence The document is a formal announcement of resolutions passed at the 17th meeting of the 3rd Board of Directors of Chongqing Huashen Pharmaceutical Co., Ltd. It details the meeting's attendance, the approval of a subsidiary's acquisition of equity in another company, and the provision of guarantees by the company. The document includes voting results and references to related announcements published elsewhere. There is no financial data or detailed report content; rather, it is a disclosure of board decisions and management actions. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the company's board or senior management.
2025-05-14 Chinese
关于公司全资子公司受让成都奥睿药业有限公司股权及公司为全资子公司提供对外担保的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Chongqing Huashen Pharmaceutical Co., Ltd. regarding its wholly-owned subsidiary acquiring equity in Chengdu Aorui Pharmaceutical Co., Ltd. It includes comprehensive information about the transaction, parties involved, financial data, audit report references, board meeting resolutions, and guarantees provided. The content focuses on a capital investment transaction, equity transfer, and related corporate governance changes. It is not a full annual or interim financial report, nor is it a simple announcement of a report publication. The document is too detailed and lengthy to be a mere announcement and contains substantive transaction and financing details. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2025-05-14 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.